Entropy NeurodynamicsASX: ENP
Also known as: Tryptamine Therapeutics Limited, Tryp Therapeutics
Entropy Neurodynamics Limited (formerly Tryptamine Therapeutics Limited, renamed November 2025; ASX: ENP, OTC: TYPTF) is an Australian clinical-stage company developing psilocin-based therapies for conditions with major unmet need including fibromyalgia, binge eating disorder, and IBS. Its two-pronged strategy uses TRP-8802 (oral psilocybin) to establish clinical proof-of-concept, then advances TRP-8803 (proprietary IV psilocin formulation) for precision dosing. Phase 2a fibromyalgia and BED trials showed strong results; the world's first IV psilocin neuropsychiatric trial (TRP-8803 in BED) dosed its first patient on December 1, 2025 at Swinburne University.
Drug Pipeline
4TRP-8802
PsilocybinFibromyalgia. Oral psilocybin + psychotherapy. Phase 2a at University of Michigan: positive results in all 5 patients — improvements in fibromyalgia pain severity, sleep, pain interference, and ≥3 other endpoints.
TRP-8802
PsilocybinBinge eating disorder (BED). Oral psilocybin + psychotherapy. Phase 2a (n=6): 80% reduction in binge episodes sustained through Week 14; improvements in anxiety, depression, psychological inflexibility, and waist circumference. Well tolerated.
TRP-8802
PsilocybinIrritable bowel syndrome (IBS) with chronic abdominal pain. Oral psilocybin. IND submitted to FDA for Phase 2 trial at Harvard Medical School/Massachusetts General Hospital. Primary endpoint: abdominal pain improvement.
TRP-8803
PsilocybinBinge eating disorder (and broader neuropsychiatric/pain indications). Proprietary IV-infused psilocin formulation enabling precise dose control, onset, and duration. World's first IV psilocin neuropsychiatric trial: first patient dosed December 1, 2025 at Swinburne University (140-minute infusion). Designed to improve on the variable absorption of oral psilocybin.
Quick Facts
- Type
- Public Biotech
- Ticker
- ASX: ENP
- Lead Stage
- Phase II
- HQ
- Australia, Australia
- Website
- Visit